Unichem Laboratories has received final ANDA approval for its Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Boehringer Ingelheim Pharmaceuticals Inc.'s Mirapexe Tablets, 0.125 mg. 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg.
Pramipaxole Dihydrochloride Tablets are indicated for the treatment of Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS).
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.
